Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens

LEM Oosten, MED Chamuleau, Frederick Thielen, LC de Wreede, Claire Siemes, Jeanette Doorduijn, OS Smeekes, MJ Kersten, L Hardi, JW Baars, AMP Demandt, WBC Stevens, GW Nijland, Carin Uyl - de Groot, PM Kluin, D de Jong, H Veelken

Research output: Contribution to journalArticleAcademicpeer-review

26 Citations (Scopus)
20 Downloads (Pure)


Burkitt lymphoma is an aggressive B cell malignancy accounting for 1–2% of all adult lymphomas. Treatment with dose-intensive, multi-agent chemotherapy is effective but associated with considerable toxicity. In this observational study, we compared real-world efficacy, toxicity, and costs of four frequently employed treatment strategies for Burkitt lymphoma: the Lymphome Malins B (LMB), the Berlin-Frankfurt-Münster (BFM), the HOVON, and the CODOX-M/IVAC regimens. We collected data from 147 adult patients treated in eight referral centers. Following central pathology assessment, 105 of these cases were accepted as Burkitt lymphoma, resulting in the following treatment groups: LMB 36 patients, BFM 19 patients, HOVON 29 patients, and CODOX-M/IVAC 21 patients (median age 39 years, range 14–74; mean duration of follow-up 47 months). There was no significant difference between age, sex ratio, disease stage, or percentage HIV-positive patients between the treatment groups. Five-year progression-free survival (69%, p = 0.966) and 5-year overall survival (69%, p = 0.981) were comparable for all treatment groups. Treatment-related toxicity was also comparable with only hepatotoxicity seen more frequently in the CODOX/M-IVAC group (p = 0.004). Costs were determined by the number of rituximab gifts and the number of inpatients days. Overall, CODOX-M/IVAC had the most beneficial profile with regards to costs, treatment duration, and percentage of patients completing planned treatment. We conclude that the four treatment protocols for Burkitt lymphoma yield nearly identical results with regards to efficacy and safety but differ in treatment duration and costs. These differences may help guide future choice of treatment.
Original languageEnglish
Pages (from-to)255-266
Number of pages12
JournalAnnals of Hematology
Issue number2
Publication statusPublished - 6 Dec 2017

Research programs

  • EMC 06-05-63-01-02 iMTA
  • EMC NIHES-05-63-01 Management
  • EUR ESHPM 02


Dive into the research topics of 'Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens'. Together they form a unique fingerprint.

Cite this